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Abstract: Intraductal carcinoma (IC) is the new WHO designation for tumors previously encompassed
by ”low-grade cribriform cystadenocarcinoma” and ”low-grade salivary duct carcinoma.” The relationship
of IC to salivary duct carcinoma (SDC) is controversial, even though they are considered to be distinct
entities. IC is a rare low-grade malignant salivary gland neoplasm with histopathological features reminis-
cent of atypical ductal hyperplasia or ductal carcinoma in situ of the breast, showing diffuse S100 protein
and mammaglobin positivity, while it is partially defined genetically. Recently, RET rearrangements
including NCOA4-RET and TRIM27-RET have been described in IC. Here, we genetically characterize
the largest cohort of IC to date (33 cases) including 8 cases with focal or widespread invasive growth and
1 case with lymph node metastasis. Thirty-three cases of IC were analyzed by next-generation sequencing
(NGS) using the FusionPlex Solid Tumor kit (ArcherDX). Identified gene fusions were confirmed using
fluorescence in situ hybridization break-apart and fusion probes and an reverse transcription polymerase
chain reaction designed specifically for the detected breakpoints. Ten cases of SDC were analyzed for
comparison using NGS panels that detect mutations and fusion transcripts. NGS analysis detected an
NCOA4-RET fusion transcript in 11 cases of intercalated duct-type IC joining exon 7 or 8 of NCOA4
gene and exon 12 of the RET gene. Eight cases of IC had an invasive growth pattern, including one with
widespread invasion and lymph node metastasis. Three invasive ICs harbored an NCOA4-RET fusion
transcript, while 1 case was negative, and 2 cases were not analyzable. In addition, a novel TRIM27-
RET fusion transcript between exon 3 of TRIM27 and exon 12 of RET was identified in 2 cases of IC
with apocrine features, and one of them displayed invasive growth. Two IC cases with invasive growth
harbored novel fusions TUT1-ETV5 and KIAA1217-RET, respectively. A total of 42.4% of the cases in
this series of IC harbored fusions involving RET. Such fusion transcripts were not detected in any of the
10 SDC cases. We have confirmed NCOA4-RET as a predominant fusion in intercalated duct-type IC,
including 3 cases with invasive growth pattern. A novel finding in our series was a case of widely invasive
intercalated duct-type IC, with a single lymph node metastasis that revealed an NCOA4-RET fusion
transcript. We also demonstrated that a subset of apocrine ICs harbored a TRIM27-RET gene fusion,
including one case with invasive growth. In contrast, neither NCOA4-RET nor TRIM27-RET fusions
were detected in any tested SDCs. Thus, the distinct molecular findings in IC and SDC support that the
tumors are separate malignant salivary tumor entities. The presence of tumor-type-specific NCOA4-RET
or TRIM27-RET translocations in a subset of widely invasive carcinomas with intercalated duct-like im-
munoprofiles suggests that a recharacterization of IC including its redesignation as ”intercalated duct
carcinoma, invasive or noninvasive” may be appropriate.
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Abstract: Intraductal carcinoma (IC) is the new WHO designation
for tumors previously encompassed by “low-grade cribriform cys-
tadenocarcinoma” and “low-grade salivary duct carcinoma.” The
relationship of IC to salivary duct carcinoma (SDC) is controversial,
even though they are considered to be distinct entities. IC is a rare
low-grade malignant salivary gland neoplasm with histopatho-
logical features reminiscent of atypical ductal hyperplasia or ductal
carcinoma in situ of the breast, showing diffuse S100 protein and
mammaglobin positivity, while it is partially defined genetically.
Recently, RET rearrangements including NCOA4-RET and
TRIM27-RET have been described in IC. Here, we genetically
characterize the largest cohort of IC to date (33 cases) including 8
cases with focal or widespread invasive growth and 1 case with
lymph node metastasis. Thirty-three cases of IC were analyzed by
next-generation sequencing (NGS) using the FusionPlex Solid
Tumor kit (ArcherDX). Identified gene fusions were confirmed
using fluorescence in situ hybridization break-apart and fusion
probes and an reverse transcription polymerase chain reaction
designed specifically for the detected breakpoints. Ten cases of
SDC were analyzed for comparison using NGS panels that detect
mutations and fusion transcripts. NGS analysis detected an
NCOA4-RET fusion transcript in 11 cases of intercalated duct-
type IC joining exon 7 or 8 of NCOA4 gene and exon 12 of the
RET gene. Eight cases of IC had an invasive growth pattern,
including one with widespread invasion and lymph node meta-
stasis. Three invasive ICs harbored an NCOA4-RET fusion
transcript, while 1 case was negative, and 2 cases were not ana-
lyzable. In addition, a novel TRIM27-RET fusion transcript be-
tween exon 3 of TRIM27 and exon 12 of RET was identified in 2
cases of IC with apocrine features, and one of them displayed
invasive growth. Two IC cases with invasive growth harbored
novel fusions TUT1-ETV5 and KIAA1217-RET, respectively. A
total of 42.4% of the cases in this series of IC harbored fusions
involving RET. Such fusion transcripts were not detected in any of
the 10 SDC cases. We have confirmed NCOA4-RET as a pre-
dominant fusion in intercalated duct-type IC, including 3 cases
with invasive growth pattern. A novel finding in our series was a
case of widely invasive intercalated duct-type IC, with a single
lymph node metastasis that revealed an NCOA4-RET fusion
transcript. We also demonstrated that a subset of apocrine ICs
harbored a TRIM27-RET gene fusion, including one case with
invasive growth. In contrast, neither NCOA4-RET nor
TRIM27-RET fusions were detected in any tested SDCs. Thus,
the distinct molecular findings in IC and SDC support that the
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tumors are separate malignant salivary tumor entities. The pres-
ence of tumor-type–specific NCOA4-RET or TRIM27-RET
translocations in a subset of widely invasive carcinomas with in-
tercalated duct-like immunoprofiles suggests that a recharacteri-
zation of IC including its redesignation as “intercalated duct
carcinoma, invasive or noninvasive” may be appropriate.
Key Words: salivary gland neoplasms, intraductal carcinoma,
intercalated duct carcinoma, apocrine, NCOA4-RET,
TRIM27-RET, RET-targeted therapy, gene fusion, cohort
studies
(Am J Surg Pathol 2019;00:000–000)
In the 2017 World Health Organization Classification ofHead and Neck Tumours,1 the tumor entity originally
described as “low-grade salivary duct carcinoma”2 and
later called “low-grade cribriform cystadenocarcinoma”3
was renamed as intraductal carcinoma (IC). IC is a rare
low-grade salivary gland malignancy with histomorpho-
logic features reminiscent of atypical ductal hyperplasia or
ductal carcinoma in situ of the breast. The tumor is, in
typical cases, characterized by intraductal and intracystic
proliferation of luminal ductal cells exhibiting solid, cri-
briform, and papillary patterns. Its in situ intraductal
nature is demonstrated by an intact myoepithelial cell
layer highlighted by antibodies to p63 protein, calponin,
and/or cytokeratin 14. IC typically shows an intercalated
duct phenotype demonstrating S100 protein and SOX10
positivity of luminal cells, while a subset of IC shows
apocrine morphology further supported by androgen re-
ceptor (AR) immunoexpression.4 Rare lesions show mixed
features of the 2 (hybrid types).
Recent studies investigating the molecular genetics
of IC showed recurrent rearrangements of the RET gene
with a predominant NCOA4-RET fusion in the interca-
lated duct-type IC,5,6 and a TRIM27-RET fusion in the
apocrine-type IC.6,7 Recurrent rearrangements involving
RET have been identified in 47% of cases of low-grade IC
with S100 positivity and intercalated duct phenotype.5,6
NCOA4-RET fusion was described in noninvasive IC, and
the RET gene was identified as an apparent early onco-
genic driver.5,6 Interestingly, rare but well-documented
cases of IC with focal or widespread invasive growth have
been reported.4,6 Although previous cases of IC with mi-
croinvasion were known,2,8,9 the first case of S100 protein–
positive and AR-negative intercalated duct-type IC with
NCOA4-RET gene fusion and an invasive component was
described recently by Weinreb et al (case 1).5 In our pre-
vious study, we reported invasive growth in one case of IC
with apocrine features and TRIM27-RET gene fusion
(case 3).6 Thus, there is a growing body of evidence in-
dicating that RET-rearranged ICs are not always indolent
in situ malignancies, but may be widely invasive.
Moreover, RET-rearranged IC cases with hybrid in-
tercalated duct and apocrine features have been reported.5,7
These findings, in particular, intercalated predominant and
pure apocrine carcinomas with widely invasive growth
patterns and RET rearrangement suggest that the current
term “intraductal carcinoma” (WHO 2017)1 should be re-
placed by a more appropriate designation. It is the opinion
of the authors of this study that the term “intraductal car-
cinoma” is a misnomer because of cases with widely in-
vasive carcinomas with a background of in situ intraductal
low-grade lesions harboring NCA4-RET or TRIM27-RET
gene fusions. To support this hypothesis, we have genetically
characterized the largest cohort of IC to date (33 cases),
including 8 cases with focal to widespread invasive growth
and 1 case with lymph node metastasis. The relationship of
IC to salivary duct carcinoma (SDC) has been controversial
since the first description of IC.2,8–13 Ten cases of SDC were
analyzed for comparison using next-generation sequencing
(NGS) panels that detect mutations and fusion transcripts.
MATERIALS AND METHODS
Among > 6200 cases of primary salivary gland tu-
mors, 33 cases of IC were retrieved from the consultation
files of the Salivary Gland Tumor Registry, at the De-
partment of Pathology, Faculty of Medicine in Plzen, and
Biopticka Laboratory Ltd, Plzen, Czech Republic, and
from the consultation files of the coauthors. Twenty-nine
cases originally diagnosed as SDC were, for comparison,
retrieved from the consultation files of the Salivary Gland
Tumor Registry, and 10 of them were analyzed by NGS.
The histopathologic features of all tumors and the
immunohistochemical stains, when available, were re-
viewed by 3 pathologists (A.S., T.S., and M.B.). A diag-
nosis of IC was confirmed in cases that displayed
histologic features consistent with the original description
in conjunction with the appropriate immunohistochemical
profile, that is, co-expression of S100 protein, cytokeratin
CK7, and mammaglobin in the absence of DOG1 stain-
ing. Moreover, an intact myoepithelial layer decorated by
p63 and/or CK14 and calponin provided evidence of the
intraductal component. Tumors were classified further
into 2 groups, according to criteria published recently4:
those that showed an intercalated duct phenotype and
those with an apocrine phenotype. This was determined
both histologically and immunohistochemically. Thus, a
total of 33 IC cases were studied by NGS using ArcherDX
Fusion Plex kit.
A diagnosis of SDC was confirmed in cases that dis-
played histologic features consistent with original description
in conjunction with the appropriate immunohistochemical
profile, using criteria published recently.14
For conventional microscopy, the excised tissues
were fixed in formalin, routinely processed, embedded in
paraffin (FFPE), cut, and stained with hematoxylin
and eosin.
For immunohistochemical analysis, 4-μm-thick sec-
tions were cut from paraffin blocks and mounted on pos-
itively charged slides (TOMO, Matsunami Glass IND,
Japan). Sections were processed on a BenchMark ULTRA
(Ventana Medical System, Tucson, AZ), deparaffinized,
and then subjected to heat-induced epitope retrieval by
immersion in a CC1 solution at pH 8.6 at 95°C. All primary
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antibodies used are summarized in Table 1. The bound
antibodies were visualized using the ultraView Universal
DAB Detection Kit (Roche) and ultraView Universal
Alkaline Phosphatase Red Detection Kit (Roche). The
slides were counterstained with Mayer’s hematoxylin.
Appropriate positive and negative controls were used.
Where available, clinical follow-up was obtained from
the patients, their physicians, or from referring pathologists.
Molecular Genetic Study
Sample Preparation for NGS and Reverse
Transcription Polymerase Chain Reaction
For NGS and reverse transcription polymerase
chain reaction (RT-PCR) analysis, 2 to 3 FFPE sections
(10 µm thick) were macrodissected to isolate tumor-rich
regions. Samples were extracted for total nucleic acid us-
ing Agencourt FormaPure Kit (Beckman Coulter, Brea,
CA). The RNA integrity was evaluated using PreSeq
RNA QC Assay, as was previously described.6
RNA Integrity Assessment and Library Preparation
for NGS
Unless otherwise indicated, 250 ng of FFPE RNA
was used as input for NGS library construction. To assess
RNA quality, the PreSeq RNA QC Assay using iTaq
Universal SYBR Green Supermix (Biorad, Hercules, CA)
was performed on all samples during library preparation
to generate a measure of the integrity of RNA (in the form
of a cycle threshold [Ct] value). Library preparation and
RNA QC were performed following the Archer Fusion-
Plex Protocol for Illumina (ArcherDX Inc.). The Archer
FusionPlex Solid Tumor Kit was used. Final libraries were
diluted 1:100,000 and quantified in a 10 µL reaction fol-
lowing the Library Quantification for Illumina Libraries
protocol and assuming a 200 bp fragment length (KAPA,
Wilmington, MA). The concentration of final libraries was
around 200 nM. Threshold representing the minimum
molar concentration for which sequencing can be robustly
performed was set at 50 nM.
NGS Sequencing and Analysis
Libraries were diluted to 4 nM and sequenced on a
NextSeq sequencer (Illumina, San Diego, CA). The opti-
mal number of raw reads per sample was set to 3 million.
Library pools were diluted to 1.6 pM library stock with
20% 1.8 pM PhiX and loaded in the NextSeq cartridge.
The fusion and other rearrangement detection algo-
rithm in Archer Analysis relies on the specificity of the gene-
specific primers used in the amplification steps in the AMP
process. The resulting FASTQ files were analyzed using the
Archer Analysis software (version 5.1.7; ArcherDX Inc.).
Fluorescence In Situ Hybridization Analysis of RET
Break and TRIM27-RET Fusion
Four-micrometer-thick FFPE sections were placed
onto positively charged slides. Hematoxylin and eosin–
stained slides were examined for determination of areas
for cell counting.
The unstained slides were deparaffinized and incubated
in the 1× Target Retrieval Solution Citrate pH 6 (Dako,
Glostrup, Denmark) at 95°C for 40 minutes and subsequently
cooled for 20 minutes at room temperature in the same sol-
ution. The slides were washed in deionized water for 5 mi-
nutes and digested in protease solution with Pepsin (0.5mg/
mL) (Sigma Aldrich, St. Louis, MO) in 0.01M HCl at 37°C
for 35 to 60 minutes according to the sample conditions. The
slides were then placed into deionized water for 5 minutes,
dehydrated in a series of ethanol solution (70%, 85%, and
96% for 2min each), and air-dried.
For the detection of RET rearrangement, factory
premixed commercial probe ZytoLight SPEC RET Dual
Color Break Apart Probe (ZytoVision GmbH, Bre-
merhaven, Germany) was used. For the TRIM27-RET
dual-fusion detection custom-designed SureFISH probe
(Agilent Technologies Inc., Santa Clara) with chromoso-
mal regions chr6:28631476-29131075 and chr10:43354893-
43849282 was used. Probe mixture for fusion detection
was prepared from corresponding probes (each color was
delivered in a separated well), deionized water, and LSI
Buffer (Vysis/Abbott Molecular) in a 1:1:1:7 ratio, re-
spectively.
An appropriate amount of mixed and premixed
probes was applied on specimens, covered with a glass
coverslip, and sealed with rubber cement. The slides were
incubated in the ThermoBrite instrument (StatSpin/Iris
Sample Processing, Westwood, MA) with co-denaturation
at 85°C/8 minutes and hybridization at 37°C/16 hours.
The rubber-cemented coverslip was then removed, and the
slide was placed in posthybridization wash solution
(2xSSC/0.3% NP-40) at 72°C/2 minutes. The slide was air-
dried in the dark, counterstained with 4′, 6′-diamidino-
2-phenylindole DAPI (Vysis/Abbott Molecular), cover
slipped, and immediately examined.
Fluorescence In Situ Hybridization Interpretation
The sections were examined with an Olympus
BX51 fluorescence microscope (Olympus Corporation,
Tokyo, Japan) using a ×100 objective and filter sets






S-100 protein Polyclonal RTU CC1/20min Ventana




p63 4A4 RTU CC1/64min Ventana
SOX-10 Polyclonal 1:100 CC1/64min Cell Marque
MIB1 30-9 RTU CC1/64min Ventana
Androgen
receptor
SP107 RTU CC1/64min Cell Marque
Calponin EP798Y RTU CC1/36min Cell Marque
CK 14 SP53 RTU CC1/64min Cell Marque
CC1 indicates EDTA buffer, pH 8.6; RTU, ready to use.
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Triple Band Pass (DAPI/SpectrumGreen/SpectrumOrange),
Dual Band Pass (SpectrumGreen/SpectrumOrange), and
Single Band Pass (SpectrumGreen or SpectrumOrange).
For each probe, 100 randomly selected nonoverlapping
tumor cell nuclei were examined for the presence of yellow or
green and orange fluorescent signals. As regards break-apart
probe, yellow signals were considered negative, and separate
orange and green signals were considered as positive; con-
versely, for fusion probe, yellow signals were considered
positive, and separate orange and green signals were consid-
ered as negative. Cut-off values for break-apart and fusion
probes were set to >10% and 20% of nuclei with chromo-
somal breakpoint and fusion signals, respectively (mean+3
SD in normal non-neoplastic control tissues).
RT-PCR Analysis of NCOA4-RET and
TRIM27-RET Fusion Transcripts
Two sample of cDNA prepared by standard reverse
transcription procedure using Transcriptor First Strand
cDNA Synthesis Kit (RNA input 500 ng) (Roche Diag-
nostics, Mannheim, Germany) was added to the reaction
mixture consisting of 12.5 µL of HotStar Taq PCR Master
Mix (QIAgen, Hilden, Germany), 10 pmol of each fusion-
specific primer (Table 2), and distilled water up to 25 µL.
The amplification program comprised denaturation at 95°
C for 14 minutes and then 45 cycles of denaturation at 95°
C for 1 minute, annealing at a temperature of 55°C for
1 minute and extension at 72°C for 1 minute. The program
was completed by incubation at 72°C for 7 minutes.
Successfully amplified PCR products were purified with
magnetic particles Agencourt AMPure (Agencourt Bioscience
Corporation, A Beckman Coulter Company, Beverly, MA).
Products were then bidirectionally sequenced using Big Dye
Terminator Sequencing kit (Applied Biosystems, Foster City,
CA), purified with magnetic particles Agencourt CleanSEQ
(Agencourt Bioscience Corporation), all according to the
manufacturer’s protocol, and run on an automated sequencer
ABI Prism 3130×l (Applied Biosystems) at a constant voltage
of 13.2 kV for 11 minutes.
RESULTS
Molecular Genetic Findings
Thirty-three cases of IC were analyzed by NGS us-
ing the Anchored Multiplex PCR (AMP) chemistry tech-
nique (ArcherDX). An NCOA4-RET fusion transcript
joining exon 7 or 8 of the NCOA4 gene and exon 12 of the
RET gene was detected in 11 cases of intercalated duct or
hybrid types of IC. A novel TRIM27-RET fusion tran-
script between exon 3 of TRIM27 and exon 12 of RET
was detected in 2 cases with histologic and im-
munohistochemical features typical of the apocrine var-
iant of IC. Two IC cases with invasion harbored novel
fusions TUT1-ETV5 and KIAA1217-RET, respectively.
The fusion transcripts were confirmed by RT-PCR and by
sequencing. Fluorescence in situ hybridization (FISH)
analysis using RET break-apart probe showed 2 different
patterns. One was deemed “negative” when distance cri-
teria of the break-apart probe were used according to in-
terpretation rules, even if a minor separation of signals
was seen (cases 1 to 2, 8, 15 to 19, 26, and 29). The other
pattern showed a regular break (classic positive pattern)
with separation of signals detected in 3 cases (cases 3, 28,
and 31). Confirmation using FISH TRIM27-RET fusion
probe displayed fusion signals with amplification. Local-
ization of RET, NCOA4, and TRIM27 genes to obtain an
explanation of the 2 different patterns in FISH break-
apart results is shown in the Figure 1.
A total of 42.4% of the analyzed cases harbored an
RET fusion by NGS. This was less than that in previous
reports,5,6 but almost one-third of our cases were found not
analyzable (NA). By RT-PCR, the fusions NCOA4-RET
and TRIM27-RET were confirmed in all NGS-positive
cases. The RET break-apart probe and the TRIM27-RET
fusion probe successfully detected rearrangement in both
cases with TRIM27-RET fusion identified by NGS. Only a
narrow separation of the FISH signals for RET rearrange-
ment was obtained, as this rearrangement contains an in-
trachromosomal inversion. Such “false”-negative FISH
results were obtained for all NCOA4-RET cases. The mo-
lecular findings are summarized in Tables 3 and 4.
Ten cases of high-grade salivary carcinomas, originally
diagnosed as SDC, were analyzed by NGS using the Fusion
Plex Solid Tumor and Comprehensive Thyroid and Lung
(CTL) kits for Illumina (ArcherDX). The analysis revealed
one case harboring an ETV6-NTRK3 fusion, and therefore it
was reclassified as a high-grade secretory carcinoma. NGS
also detected 5 likely pathogenic mutations in 5 SDC cases
(HRAS: c.182A>G p.Gln61Arg, HRAS: c.37G>C p.
Gly13Arg, AKT1: c.49G>A p.Glu17Lys, PTEN c.1003C>
T p.Arg335Ter). Homozygous deletion of locus 9p21
(CDKN2A) was detected in one case harboring an HRAS
mutation. Two cases presented rearrangement of the MYB
gene, while one case was positive for PLAG1 rearrangement.
MDM2 amplification was found in one case harboring also a
PTEN mutation. The other SDC cases were negative for
MDM2 amplification and showed no rearrangement in the
genes MYB, MYBL1, NFIB, NTRK1, RET, and PLAG1.
Neither NCOA4-RET nor TRIM27-RET fusions were de-
tected in any SDC cases.
Clinical and Histologic Characteristics of the
Study Group
The study series consisted of 33 ICs; 25 neoplasms were
pure intraductal in situ lesions, while 8 cases showed apparent
TABLE 2. Primers Used for RT-PCR Analysis











Skálová et al Am J Surg Pathol  Volume 00, Number 00, ’’ 2019
4 | www.ajsp.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
invasive growth, in one case with a single metastasis in a
periparotideal lymph node. The invasive carcinomas occurred
in patients ranging in age from 36 to 64 years (mean: 52.5 y),
and noninvasive IC in patients ranging in age from 17 to
81 years (mean: 56 y). The most common anatomic site of
involvement was the parotid gland (n=28), and there was 1
case each in the buccal mucosa, the palate, and the sub-
mandibular gland. Detailed clinical and histopathologic
findings and follow-up information of 33 patients with IC are
summarized in Table 4.
Microscopic and Immunohistochemical Features
Histologically, at low-power magnification, the ICs were
well circumscribed and encapsulated in most cases. They were
characterized by luminal epithelial proliferations with interca-
lated duct phenotype arranged mainly in multiple cystic pat-
terns, besides solid and cribriform islands in 24/33 (73%)
(Fig. 2A). Intracystic growth often formed micropapillary
structures with anastomosing epithelial tufts, with snouts,
decapitation secretion, and apocrine features in 6/33 cases
(18%) (Fig. 2C). A hybrid intercalated duct and apocrine
growth pattern were seen in 4/33 cases (12%). Widespread or
focal invasive growth was found in 8 cases. In the cases of
invasion, we estimate that the invasive component ranged
roughly from 10 to 60% of the total tumor area. While no
peritumoral lymphovascular invasion was noted in the IC
cases, perineural invasion (Fig. 3A) and metastatic infiltration
in a periparotid lymph node were observed in 1 case (Fig. 3B).
Invasive areas revealed a compressed fibrotic stroma with
desmoplasia. Case 6 was an unusual multinodular invasive
low-grade carcinoma of the parotid gland composed of 2
distinctive growth patterns. A large part of the tumor was a
low-grade salivary epithelial-myoepithelial carcinoma with
apocrine differentiation in both the luminal epithelial and the
abluminal myoepithelial cells, and it had a broadly invasive
growth pattern. Another section of the same tumor revealed a
noninvasive IC, of the intercalated duct type, with intracystic
papillary and cribriform features.
FIGURE 1. A–C, Sanger sequencing analysis of RT-PCR generated fusion transcripts NCOA4-RET (exon joining 7 to 12),
NCOA4-RET (exon joining 8 to 12), and TRIM27-RET (exon joining 3 to 12). The arrow shows the fusion position.
Am J Surg Pathol  Volume 00, Number 00, ’’ 2019 NCOA4-RET and TRIM27-RET Fusions in Salivary IC
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. www.ajsp.com | 5
Copyright r 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.




















1 38/M Pure IC intercalated duct type, solid
microcystic, rich lymphoid stroma
NCOA4-RET 8-12 Positive* ND Positive Negative Negative
2 47/M Pure IC intercalated duct type, solid
multicystic
NCOA4-RET 7-12 Positive* ND Positive Negative Negative
3 54/M IC with apocrine features,
micropapillary, invasive
TRIM27-RET 3-12 Positive Positive Positive Negative Negative
4 50/M Pure IC intercalated duct type, solid
multicystic
NA — NA ND Negative Negative Negative
5 58/M Pure IC hybrid intercalated duct and
apocrine type, solid microcystic,
papillary
NA — NA ND ND NA Negative
6 81/M Pure IC intercalated duct type, “roman
bridges”
Invasive component of epithelial-
myoepithelial ca
NA — Negative ND Negative Negative Negative
7 50/F Pure IC intercalated duct type, unicystic Negative — Negative ND ND Negative Negative
8 74/M Pure IC intercalated duct type, papillary,
multicystic
NCOA4-RET 8-12 Positive* ND Positive Negative Negative
9 36/F Pure IC intercalated duct type, few
apocrine cells
Negative — Negative ND ND Negative Negative
10 53/F IC intercalated duct type, stromal
invasion, perineural invasion
Negative — Negative ND ND Negative Negative
11 75/F IC with apocrine features, papillary, thick
fibrous capsule
Negative — Negative ND ND Negative Negative
12 69/M IC with apocrine features, unicystic Negative — ND ND ND ND Negative
13 42/F Pure IC intercalated duct type, unicystic Negative — ND ND ND Negative Negative
14 75/F Pure IC intercalated duct type, solid,
microcystic
Negative — Negative ND Negative Negative Negative
15 61/F Pure IC intercalated duct type, solid,
microcystic
NCOA4-RET 7-12 Positive* ND Positive NA Negative
16 36/M Pure IC intercalated duct type, solid,
microcystic
NCOA4-RET 8-12 Positive* ND Positive ND ND
17 50/M IC with widespread apocrine features, and
hybrid intercalated duct pattern
NCOA4-RET 8-12 Positive* Positive Positive ND ND
18 36/M IC intercalated duct pattern with
widespread stromal invasion,
periparotideal lymph node metastasis
NCOA4-RET 8-12 Positive* ND Positive Negative ND
19 48/M IC intercalated duct type, solid
microcystic
NCOA4-RET 8-12 ND ND ND ND ND
20 54/M Pure IC with apocrine features Negative — ND ND ND ND ND
21 51/M Pure IC with widespread apocrine
features, and hybrid intercalated duct
pattern
Negative — ND ND ND ND ND
22 71/F Pure IC intercalated duct type, solid
microcystic
Negative — ND ND ND ND ND
23 64/M Pure IC intercalated duct type NA — ND ND ND ND ND
24 70/M Pure IC intercalated duct type NA — ND ND ND ND ND
25 17/M IC intercalated duct type, solid,
microcystic
NA — ND ND ND ND ND
26 55/F IC intercalated duct type, solid,
macrocystic, focally invasive
NCOA4-RET 7-12 ND ND ND ND ND
27 59/M IC intercalated duct type, solid,
macrocystic, focally invasive
NA — ND ND ND ND ND
28 66/M IC, apocrine variant, intracystic papillary
and micropapillary structures
predominate, focal intercalated duct
type of growth with solid pattern, no
invasive growth
TRIM27-RET 3-12 Positive Positive Positive ND ND
29 52/M IC, predominantly in situ intercalated
duct variant, focally invasive
NCOA4-RET 7-12 ND ND Positive ND ND
30 64/M IC, intercalated duct variant, focally
invasive
TUT1-ETV5 7-8 ND ND NA ND ND
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On high-power magnification, all cases showed bland
cytologic features, with tumor cells ranging from small to
medium size. They had indistinct cell borders and round or
ovoid nuclei with dark condensed or finely dispersed chro-
matin and large pale to eosinophilic cytoplasm. None of the
cases in this study had an oncocytic morphology, although an
oncocytic variant has been described in the literature.15 Mi-
toses were inconspicuous. In all 8 IC cases with invasive
growth, we have seen compressed sclerotic fibrosis repre-
senting apparent desmoplastic reaction around the invasive
foci of the tumors (Fig. 3C). These invasive ICs did not have
higher MIB1 indices. Proliferative activity in ICs was
generally low, with a mean MIB1 index <5% (ranging from
1% to 10%). No difference was seen between invasive and
noninvasive ICs.
The tumor islands of IC were surrounded by a layer of
myoepithelial cells, as evidenced by the immunohistochemical
expression of p63, calponin, and/or CK 14 (all of which were
negative in luminal epithelial tumor cells) in a continuous
abluminal pattern in 14/33 cases (43%) (Fig. 2B). A partly
discontinuous immunostaining for p63 was seen in most cases
(Fig. 3D). All IC cases assessed as completely intraductal
were examined in total and stained with antibodies to
calponin and p63/p40. Thus, hematoxylin and eosin–based
information was verified by continuous immunostains corre-
sponding to intact myoepithelial cell layers. In ICs with
apocrine and mixed hybrid growth patterns (10/33 cases;
30%), most tumor cells were positive for nuclear AR
(Fig. 2D). Diffuse and strong coexpression of S100 protein,
mammaglobin, and SOX10 was detected in 24/33 cases
(73%). Pure apocrine ICs were positive for AR and negative
for S100 protein/SOX10 and mammaglobin in 4 cases, while,
in one case, AR was strongly expressed together with S100
protein/SOX10 and mammaglobin.
DISCUSSION
The term “intraductal carcinoma” of the salivary gland
was first introduced in 1983 by Chen10 in a description of a
single case arising in the minor salivary gland of the oral
cavity. Subsequently, several case reports and small series
of the same tumor entity were published with various names,
including “low-grade salivary duct carcinoma”2,8 and
“low-grade cribriform cystadenocarcinoma.” The latter des-
ignation was introduced by the editors of the 2005 WHO
Classification of Head and Neck Tumours, although this
term had never appeared in the literature before that point.3
This term referred to cystic and solid structures formed by
intraductal epithelial proliferation of cells resembling inter-
calated duct cells and structures reminiscent of atypical ductal
hyperplasia and ductal carcinoma in situ of the breast. In the
2017 WHO Classification of Head and Neck Tumours, this
tumor is regarded as an IC.1 IC has been surrounded by
controversy since its description not only because of variable
terminologies but primarily because of the uncertain rela-
tionship to salivary duct carcinoma.2,3,8,11 In typical cases, IC
is a noninvasive low-grade carcinoma composed of bland
neoplastic cells positive for S100 protein, in sharp contrast to
those features seen in SDC. SDC is defined by the 2017WHO
classification as an aggressive epithelial malignancy resem-
bling high-grade mammary ductal carcinoma. It is composed
of pleomorphic S100 protein-negative and AR-positive neo-
plastic cells.16 Therefore, these 2 lesions are generally accepted
as distinct and separate entities.5,6,13,14 However, the literature
describes occasional well-documented low-grade ICs with
widespread invasive growth.2,3,5,6 Even more confusing are
rare cases of true high-grade SDC reported as purely “in situ
lesions.”11 Moreover, IC cases with hybrid intercalated duct
and apocrine features,5,7 oncocytic features,15 and pure
apocrine features with diffuse AR-positive and S100 protein/
mammaglobin and/or SOX10-negative immunoprofile4,6
have been described.
In recent years, many salivary gland low-grade
carcinomas have been found to demonstrate characteristic
tumor type–specific chromosomal rearrangements, such as
ETV6-NTRK3 and ETV6-RET, in secretory carcinoma (also
known as mammary analogue secretory carcinoma),17,18
EWSR1-ATF1 and EWSR1-CREM in hyalinizing clear cell
carcinoma of minor salivary glands,19,20 CRTC1-MAML2
and CRTC3-MAML2 in mucoepidermoid carcinoma,21
ARID1A-PRKD1 and variant PRKD1, PRKD2, and
PRKD3 fusions in cribriform adenocarcinoma of minor
salivary glands and PRKD1 somatic mutations in poly-
morphous adenocarcinoma,22–24 and HTN3-MSANTD3 in
a subset of acinic cell carcinoma of the salivary gland.25 The





















31 47/F IC, hybrid intercalated duct structures
predominate, apocrine features, focally
invasive
KIAA1217-RET 14-9 Positive ND Positive ND ND
32 70/F IC, intercalated duct variant Negative — ND ND ND ND ND
33 48/F IC, intercalated duct variant NCOA4-RET 7-12 ND ND Positive ND ND
Cases 1 to 17 were published in Skálová et al.6
*Cases showed an RET FISH signal pattern indicative of an inversion/rearrangement (in one allele a gap between orange and green signals was observed; hovewer, this
gap did not reach internal cutoff (≥ 2 signal diameters apart).
F indicates female; M, male; NA, not analyzable; ND, not done.
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includes IC with an NCOA4-RET fusion reported recently.5,6
In addition, we have described a subset of IC with apocrine
morphology harboring a novel TRIM27-RET fusion.6 Inter-
estingly, one study using RNA sequencing has revealed
NCOA4-RET fusions in 2 cases of salivary gland neoplasms
classified as SDC on the basis of expression of AR.13 Both
NCOA4-RET translocated neoplasms progressed in spite of
undergoing concurrent chemoradiation, combination che-
motherapy, and dual androgen deprivation therapy. Both
patients, however, benefited from RET-targeted therapy.13
This would be a challenging finding, but the neoplasm de-
scribed as NCOA4-RET-translocated SDC, and depicted in
their Figure 3B is morphologically not compatible with
SDC.13 No reference to SOX10, mammaglobin, or S100
protein was made, while their Figure 3B shows only focal
AR staining. Therefore, it is not clear whether these
RET-translocated neoplasms are true SDCs.13 It is the
opinion of the authors that they most likely represented a
hybrid apocrine/intercalated variant of IC.
None of the above-cited gene fusions were docu-
mented in SDC cases of the previous study5 or in this
current series. In view of the tumor type–specific re-
arrangements described in salivary neoplasms so far, it is
not likely that multiple separate salivary tumor types
would have the same NCOA4-RET and RET rearrange-
ments. Thus, NCOA4-RET and TRIM27-RET gene
TABLE 4. Clinicopathologic and Molecular Findings in 33 Intraductal Carcinoma Cases
Case No. Age (y)/Sex Site Size (cm) NGS (Archer) FISH RT-PCR Outcome (mo)















4 50/M PA 1.0 NA ETV6− ETV6-NTRK3− 65 NED
5 58/M PA 1.5×1.0×0.9 NA NA ETV6-NTRK3− 152 NED
6 81/M PA — NA ETV6− ETV6-NTRK3− NAv
7 50/F PA 15 No fusion ETV6− ETV6-NTRK3− 80 NED





9 36/F Buccal mucosa 0.6 No fusion ETV6− ETV6-NTRK3− 188 NED
10 53/F PA 2.0×1.0×1.0 No fusion ETV6− ETV6-NTRK3− 188 NED
11 75/F PA 4.6×4.0×1.7 No fusion ETV6− ETV6-NTRK3− 80 NED
12 69/M PA 0.9 No fusion ND ETV6-NTRK3− 68 NED
13 42/F PA 0.7 No fusion ETV6− ETV6-NTRK3− 68 NED




15 61/F PA 1.5×1.0×1.4 NCOA4-RET ND ETV6-NTRK3− 16 NED
16 36/M PA 1.0×0.7×0.7 NCOA4-RET RET+*
ETV6− NA
ETV6-NTRK3− 16 NED
17 50/M PA 2.6 NCOA4-RET RET+* NCOA4-RET+ 20 NED
18 36/M PA 5×4×4 NCOA4-RET RET+*
NTRK3−
ETV6−
NCOA4-RET+ RT proton; 8 NED
19 48/M PA — NCOA4-RET ND ND 12 NED
20 54/M PA 1.5×8×0.5 No fusion ND ND NAv
21 51/M PA 2 No fusion ND ND NAv
22 71/F PA 1.8 No fusion ND ND NAv
23 64/M Subm — NA ND ND NAv
24 70/M PA 1.5 NA ND ND NAv
25 17/M PA 1.0 NA ND ND 96 NED
26 55/F PA 1.5 NCOA4-RET ND ND 48NED
27 59/M PA 1.2 NA ND ND 60 NED
28 66/M PA — TRIM27-RET TRIM27+
RET+†
TRIM27-RET+ NAv
29 52/M PA 2.8 NCOA4-RET ETV6−
RET+*
NCOA4-RET+ NAv
30 64/M PA 1.9 TUT1-ETV5 ND NA NAv
31 47/F PA 1.0 KIAA1217-RET ETV6−
RET+†
KIAA1217-RET+ NAv
32 70/F PA 2.5 No fusion ND ND NAv
33 48/F PA 2.4 NCOA4-RET ND NCOA4-RET+ NAv
*Cases showed an RET FISH signal pattern indicative of an inversion/rearrangement.
†Cases 3, 28, and 31 showed a classic break-apart signal pattern.
F indicates female; M, male; NA, not anlyzable; NAv, not available; ND, not done; NED, no evidence of disease; PA, parotid gland; subm, submandibular gland;
RT proton, radiotherapy in proton center.
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fusions appear to present a rather specific marker of the
intercalated duct and apocrine variants of IC, respectively,
including cases of widely invasive and metastasizing neo-
plasms. Therefore, the 2017 WHO Classification term
“intraductal carcinoma” is confusing and should be re-
placed by a more appropriate and accurate one. We pro-
pose the designation “intercalated duct carcinoma,
noninvasive (or invasive)” for neoplasms formed by in-
traductal epithelial proliferation composed of cells re-
sembling intercalated duct cells with an S100 protein/
SOX10 and mammaglobin-positive and AR-negative im-
munoprofile, and an intact or focally disrupted abluminal
myoepithelial cell layer. Thus, the intercalated duct car-
cinoma represents a line of differentiation toward inter-
calated duct features, but, in some cases, ICs may show
oncocytic,15 apocrine, or clear cell features. The neo-
plasms characterized by apocrine morphology, and an
AR-positive and S100 protein/SOX10-negative im-
munoprofile harboring the TRIM27-RET gene fusion,
should be designated “intercalated duct carcinoma, with
apocrine features.” Interestingly, we observed one case
of pure intercalated duct IC associated with invasive
low-grade epithelial-myoepithelial carcinoma (EMCa).
Fittingly, EMCa also recapitulates the intercalated duct
phenotype,26,27 and has been suggested to differentiate in
that direction. Moreover, the reported observation of
background intercalated duct hyperplasia in some cases of
EMCa suggests the possibility of an intercalated duct
precursor lesion.28,29
In contrast to IC, the well-established term “salivary
duct carcinoma” should be reserved for widely invasive
high-grade malignancies and should be classified accord-
ing to previously reported criteria.14 SDCs have shown a
number of genomic alterations including HER2-neu gene
amplification, and hotspot PIK3CA and HRAS mutations
and many others, not present in ICs.16,30–32
A novel finding in our series was a case of widely
invasive intercalated duct-type IC, with a single lymph node
metastasis that revealed an NCOA4-RET fusion transcript.
Two IC cases with invasive growth harbored novel fusions
TUT1-ETV5 and KIAA1217-RET, respectively. Finally,
NCOA4-RET and TRIM27-RET, TUT1-ETV5, and
KIAA1217-RET were not detected by NGS in any of the 10
SDCs studied as a comparison group. The molecular dis-
tinction reported herein between IC and SDC supports the
idea that they represent separate malignant salivary tumor
FIGURE 2. IC, intercalated duct variant (A, B), and apocrine variant (C, D). IC is characterized by luminal epithelial proliferations,
with intercalated duct phenotype arranged in multiple cystic patterns (A), with the intact myoepithelial abluminal layer decorated
by p63 protein in immunohistochemical staining (B). An apocrine variant of IC shows intracystic papillary structures composed of
tumor cells exhibiting abundant eosinophilic cytoplasm with apical snouts of decapitation secretion (C) and androgen receptors in
immunohistochemical staining (D).
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entities, and should be considered separately in future clas-
sifications.
In summary, recurrent rearrangements involving the
RET gene were identified in a subset of invasive and
metastasizing IC, with intercalated duct and apocrine
variants resulting in NCOA4-RET and TRIM27-RET
fusions, respectively. Patients with locally invasive, ad-
vanced, and metastatic RET-rearranged tumors could
benefit from targeted therapy using RET-inhibitors.33–36
However, the presence of oncogenic rearrangements can-
not be predicted reliably by tumor morphology only.
Therefore, we propose that salivary gland cancers should
be tested in a screening program for targetable RET al-
terations, if available. Finally, our study indicates that ICs
can also manifest significant invasive growth, and, con-
sequently, a designation of these tumors as ICs seems in-
appropriate by conventional histopathologic rules. The
authors suggest that IC should be redesignated as inter-
calated duct carcinoma, noninvasive or invasive.
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